



Quartz Medicare Advantage (HMO)

Part D Medication Step-Therapy Criteria

These step-therapy criteria apply to Quartz Medicare Advantage members for medications when filled under Medicare Part D.

ANTIDEPRESSANT THERAPY

Products Affected

Step 2:

- FETZIMA 120 MG CAPSULE, EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK
- FETZIMA 20 MG CAPSULE, EXTENDED RELEASE
- FETZIMA 40 MG CAPSULE, EXTENDED RELEASE
- FETZIMA 80 MG CAPSULE, EXTENDED RELEASE
- TRINTELLIX 10 MG TABLET
- TRINTELLIX 20 MG TABLET
- TRINTELLIX 5 MG TABLET
- VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK
- VIIBRYD 10 MG TABLET
- VIIBRYD 20 MG TABLET
- VIIBRYD 40 MG TABLET

Details

Criteria	STEP 1: Trial of two formulary generic SSRIs or SNRIs, or paroxetine suspension.
-----------------	----------------------------------------------------------------------------------

ANTIDIABETIC

Products Affected

Step 2:

- BYDUREON 2 MG/0.65 ML
SUBCUTANEOUS PEN INJECTOR
- BYDUREON BCISE 2 MG/0.85 ML
SUBCUTANEOUS AUTO-INJECTOR
- BYETTA 10 MCG/DOSE (250 MCG/ML)
2.4 ML SUBCUTANEOUS PEN INJECTOR
- BYETTA 5 MCG/DOSE (250 MCG/ML)
1.2 ML SUBCUTANEOUS PEN INJECTOR
- TRULICITY 0.75 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- TRULICITY 1.5 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- TRULICITY 3 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- TRULICITY 4.5 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR

Details

Criteria	STEP 1: Trial of metformin, glipizide, glimepiride, or pioglitazone. (Dulaglutide only): Step not required when used to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors.
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANTIDIABETIC (NONPREFERRED SGLT2)

Products Affected

Step 2:

- SEGLUROMET 2.5 MG-1,000 MG TABLET
- SEGLUROMET 2.5 MG-500 MG TABLET
- SEGLUROMET 7.5 MG-1,000 MG TABLET
- SEGLUROMET 7.5 MG-500 MG TABLET
- STEGLATRO 15 MG TABLET
- STEGLATRO 5 MG TABLET

Details

Criteria	STEP 1: Trial of metformin, glimepiride, glipizide, or pioglitazone AND a preferred formulary SGLT2 inhibitor (Farxiga, Xigduo XR, Jardiance, Synjardy, Synjardy XR)
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANTIGOUT

Products Affected

Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*

Details

Criteria	STEP 1: Trial of allopurinol
-----------------	------------------------------

ANTI-PARKINSON AGENTS

Products Affected

Step 2:

- RYTARY 23.75 MG-95 MG CAPSULE, EXTENDED RELEASE
- RYTARY 36.25 MG-145 MG CAPSULE, EXTENDED RELEASE
- RYTARY 48.75 MG-195 MG CAPSULE, EXTENDED RELEASE
- RYTARY 61.25 MG-245 MG CAPSULE, EXTENDED RELEASE

Details

Criteria	STEP 1: Trial of generic immediate-release or extended-release carbidopa/levodopa
-----------------	-----------------------------------------------------------------------------------

ASENAPINE (SECUADO)

Products Affected

Step 2:

- SECUADO 3.8 MG/24 HOUR
TRANSDERMAL 24 HOUR PATCH
- SECUADO 5.7 MG/24 HOUR
TRANSDERMAL 24 HOUR PATCH
- SECUADO 7.6 MG/24 HOUR
TRANSDERMAL 24 HOUR PATCH

Details

Criteria	STEP 1: Trial of asenapine maleate (Saphris)
-----------------	----------------------------------------------

ATOPIC DERMATITIS

Products Affected

Step 2:

- EUCRISA 2 % TOPICAL OINTMENT

Details

Criteria	STEP 1: Trial of a topical corticosteroid, topical tacrolimus, or topical pimecrolimus
-----------------	----------------------------------------------------------------------------------------

ATYPICAL ANTIPSYCHOTICS

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*
- *asenapine 10 mg sublingual tablet*
- *asenapine 2.5 mg sublingual tablet*
- *asenapine 5 mg sublingual tablet*
- CAPLYTA 42 MG CAPSULE
- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET
- LATUDA 120 MG TABLET
- LATUDA 20 MG TABLET
- LATUDA 40 MG TABLET
- LATUDA 60 MG TABLET
- LATUDA 80 MG TABLET
- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

Criteria	STEP 1: Trial of one preferred formulary oral generic atypical antipsychotic.
-----------------	-------------------------------------------------------------------------------

BLOOD PRESSURE (BETA BLOCKERS)

Products Affected

Step 2:

- BYSTOLIC 10 MG TABLET
- BYSTOLIC 2.5 MG TABLET
- BYSTOLIC 20 MG TABLET
- BYSTOLIC 5 MG TABLET

Details

Criteria	STEP 1: Trial of two alternative generic formulary beta-blockers
-----------------	------------------------------------------------------------------

BREXPIPRAZOLE (REXULTI)

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

Criteria	STEP 1: Trial of generic oral aripiprazole
-----------------	--------------------------------------------

CLOMIPRAMINE

Products Affected

Step 2:

- *clomipramine 25 mg capsule*
- *clomipramine 50 mg capsule*
- *clomipramine 75 mg capsule*

Details

Criteria	STEP 1: Trial of two formulary generic SSRIs OR TCAs
-----------------	------------------------------------------------------

DULOXETINE (DRIZALMA)

Products Affected

Step 2:

- DRIZALMA SPRINKLE 20 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 30 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 40 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 60 MG CAPSULE,DELAYED RELEASE

Details

Criteria	STEP 1: Trial of generic duloxetine capsules
-----------------	----------------------------------------------

FIBROMYALGIA

Products Affected

Step 2:

- SAVELLA 100 MG TABLET
- SAVELLA 12.5 MG TABLET
- SAVELLA 12.5 MG (5)-25 MG(8)-50MG(42) TABLETS IN A DOSE PACK
- SAVELLA 25 MG TABLET
- SAVELLA 50 MG TABLET

Details

Criteria	STEP 1: Trial of two of the following: duloxetine capsules, amitriptyline tablets, pregabalin (capsules or solution).
-----------------	-----------------------------------------------------------------------------------------------------------------------

MEMANTINE ER

Products Affected

Step 2:

- *memantine 14 mg capsule
sprinkle,extended release 24hr*
- *memantine 21 mg capsule
sprinkle,extended release 24hr*
- *memantine 28 mg capsule
sprinkle,extended release 24hr*
- *memantine 7 mg capsule
sprinkle,extended release 24hr*

Details

Criteria	STEP 1: Trial of memantine IR
-----------------	-------------------------------

PEGFILGRASTIM

Products Affected

Step 2:

- FULPHILA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE
- NYVEPRIA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE
- UDENYCA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE
- ZIEXTENZO 6 MG/0.6 ML SUBCUTANEOUS SYRINGE

Details

Criteria	STEP 1: Trial of Nivestym
----------	---------------------------

STATINS

Products Affected

Step 2:

- *fluvastatin 20 mg capsule*
- *fluvastatin 40 mg capsule*
- *fluvastatin er 80 mg tablet, extended release 24 hr*

Details

Criteria	
	STEP 1: Trial of two alternative formulary statins

VITAMIN D ANALOGS

Products Affected

Step 2:

- *doxercalciferol 0.5 mcg capsule*
- *doxercalciferol 1 mcg capsule*
- *doxercalciferol 2.5 mcg capsule*
- *paricalcitol 1 mcg capsule*
- *paricalcitol 2 mcg capsule*
- *paricalcitol 4 mcg capsule*
- RAYALDEE 30 MCG CAPSULE, EXTENDED RELEASE

Details

Criteria	STEP 1: Trial of calcitriol
----------	-----------------------------

INDEX

A

aripiprazole 10 mg disintegrating tablet	8
aripiprazole 15 mg disintegrating tablet	8
asenapine 10 mg sublingual tablet	8
asenapine 2.5 mg sublingual tablet	8
asenapine 5 mg sublingual tablet	8

B

BYDUREON 2 MG/0.65 ML SUBCUTANEOUS PEN INJECTOR	2
BYDUREON BCISE 2 MG/0.85 ML SUBCUTANEOUS AUTO-INJECTOR	2
BYETTA 10 MCG/DOSE(250 MCG/ML)2.4 ML SUBCUTANEOUS PEN INJECTOR	2
BYETTA 5 MCG/DOSE (250 MCG/ML)1.2 ML SUBCUTANEOUS PEN INJECTOR	2
BYSTOLIC 10 MG TABLET	9
BYSTOLIC 2.5 MG TABLET	9
BYSTOLIC 20 MG TABLET	9
BYSTOLIC 5 MG TABLET	9

C

CAPLYTA 42 MG CAPSULE	8
clomipramine 25 mg capsule	11
clomipramine 50 mg capsule	11
clomipramine 75 mg capsule	11

D

doxercalciferol 0.5 mcg capsule	17
doxercalciferol 1 mcg capsule	17
doxercalciferol 2.5 mcg capsule	17
DRIZALMA SPRINKLE 20 MG CAPSULE,DELAYED RELEASE	12
DRIZALMA SPRINKLE 30 MG CAPSULE,DELAYED RELEASE	12
DRIZALMA SPRINKLE 40 MG CAPSULE,DELAYED RELEASE	12
DRIZALMA SPRINKLE 60 MG CAPSULE,DELAYED RELEASE	12

E

EUCRISA 2 % TOPICAL OINTMENT	7
------------------------------	---

F

FANAPT 1 MG TABLET	8
FANAPT 10 MG TABLET	8
FANAPT 12 MG TABLET	8

FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK	8
FANAPT 2 MG TABLET	8
FANAPT 4 MG TABLET	8
FANAPT 6 MG TABLET	8
FANAPT 8 MG TABLET	8
febuxostat 40 mg tablet	4
febuxostat 80 mg tablet	4
FETZIMA 120 MG CAPSULE,EXTENDED RELEASE	1
FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK	1
FETZIMA 20 MG CAPSULE,EXTENDED RELEASE	1
FETZIMA 40 MG CAPSULE,EXTENDED RELEASE	1
FETZIMA 80 MG CAPSULE,EXTENDED RELEASE	1
fluvastatin 20 mg capsule	16
fluvastatin 40 mg capsule	16
fluvastatin er 80 mg tablet,extended release 24 hr	16
FULPHILA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE	15

L

LATUDA 120 MG TABLET	8
LATUDA 20 MG TABLET	8
LATUDA 40 MG TABLET	8
LATUDA 60 MG TABLET	8
LATUDA 80 MG TABLET	8

M

memantine 14 mg capsule sprinkle,extended release 24hr	14
memantine 21 mg capsule sprinkle,extended release 24hr	14
memantine 28 mg capsule sprinkle,extended release 24hr	14
memantine 7 mg capsule sprinkle,extended release 24hr	14

N	
NYVEPRIA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE	15
P	
paricalcitol 1 mcg capsule	17
paricalcitol 2 mcg capsule	17
paricalcitol 4 mcg capsule	17
R	
RAYALDEE 30 MCG CAPSULE,EXTENDED RELEASE	17
REXULTI 0.25 MG TABLET	10
REXULTI 0.5 MG TABLET	10
REXULTI 1 MG TABLET	10
REXULTI 2 MG TABLET	10
REXULTI 3 MG TABLET	10
REXULTI 4 MG TABLET	10
RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE	5
RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE	5
RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE	5
RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE	5
S	
SAVELLA 100 MG TABLET	13
SAVELLA 12.5 MG (5)-25 MG(8)-50MG(42) TABLETS IN A DOSE PACK	13
SAVELLA 12.5 MG TABLET	13
SAVELLA 25 MG TABLET	13
SAVELLA 50 MG TABLET	13
SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH	6
SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH	6
SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH	6

SEGLUROMET 2.5 MG-1,000 MG TABLET....	3
SEGLUROMET 2.5 MG-500 MG TABLET.....	3
SEGLUROMET 7.5 MG-1,000 MG TABLET....	3
SEGLUROMET 7.5 MG-500 MG TABLET.....	3
STEGLATRO 15 MG TABLET.....	3
STEGLATRO 5 MG TABLET.....	3
T	
TRINTELLIX 10 MG TABLET.....	1
TRINTELLIX 20 MG TABLET.....	1
TRINTELLIX 5 MG TABLET	1
TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR.....	2
TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR.....	2
TRULICITY 3 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR.....	2
TRULICITY 4.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR.....	2
U	
UDENYCA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE	15
V	
VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK.....	1
VIIBRYD 10 MG TABLET	1
VIIBRYD 20 MG TABLET	1
VIIBRYD 40 MG TABLET	1
VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK.....	8
VRAYLAR 1.5 MG CAPSULE	8
VRAYLAR 3 MG CAPSULE	8
VRAYLAR 4.5 MG CAPSULE	8
VRAYLAR 6 MG CAPSULE	8
Z	
ZIEXTENZO 6 MG/0.6 ML SUBCUTANEOUS SYRINGE	15